A multicenter retrospective study reported durable responses to talazoparib in patients with BRCA-mutant metastatic breast and ovarian cancers, reinforcing the PARP inhibitor’s activity beyond controlled trials. Investigators documented response rates, progression timelines, and safety in a real-world setting, supporting talazoparib use in advanced BRCA-driven disease and informing sequencing decisions where multiple PARP inhibitors are available.